Clinical retroviral vector production: Step filtration using clinically approved filters improves titers

L. Reeves, Kenneth Cornetta

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Production of retroviral vectors for clinical use requires removal of cells and cellular debris. We combined a series of filters of decreasing pore size using commercially available blood banking filters approved for clinical use. The collection bag and filters can be connected to create a sterile, closed system using clinically approved tubing and sealing systems. Even when challenged with a large number of vector producer cells (2.38 x 109 cells), no viable cells are passed through the system. The step filtration system developed minimizes the titer reduction associated with filtration, provides rapid flow rates, and was cost effective when filtering volumes in excess of 2 liters.

Original languageEnglish
Pages (from-to)1993-1998
Number of pages6
JournalGene Therapy
Volume7
Issue number23
DOIs
StatePublished - 2000

Fingerprint

Blood Banks
Costs and Cost Analysis

Keywords

  • Filtration
  • Retroviral vector
  • Vector titer

ASJC Scopus subject areas

  • Genetics

Cite this

Clinical retroviral vector production : Step filtration using clinically approved filters improves titers. / Reeves, L.; Cornetta, Kenneth.

In: Gene Therapy, Vol. 7, No. 23, 2000, p. 1993-1998.

Research output: Contribution to journalArticle

@article{339eea1a58a7459ea32e6599ceaf4e32,
title = "Clinical retroviral vector production: Step filtration using clinically approved filters improves titers",
abstract = "Production of retroviral vectors for clinical use requires removal of cells and cellular debris. We combined a series of filters of decreasing pore size using commercially available blood banking filters approved for clinical use. The collection bag and filters can be connected to create a sterile, closed system using clinically approved tubing and sealing systems. Even when challenged with a large number of vector producer cells (2.38 x 109 cells), no viable cells are passed through the system. The step filtration system developed minimizes the titer reduction associated with filtration, provides rapid flow rates, and was cost effective when filtering volumes in excess of 2 liters.",
keywords = "Filtration, Retroviral vector, Vector titer",
author = "L. Reeves and Kenneth Cornetta",
year = "2000",
doi = "10.1038/sj.gt.3301328",
language = "English",
volume = "7",
pages = "1993--1998",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "23",

}

TY - JOUR

T1 - Clinical retroviral vector production

T2 - Step filtration using clinically approved filters improves titers

AU - Reeves, L.

AU - Cornetta, Kenneth

PY - 2000

Y1 - 2000

N2 - Production of retroviral vectors for clinical use requires removal of cells and cellular debris. We combined a series of filters of decreasing pore size using commercially available blood banking filters approved for clinical use. The collection bag and filters can be connected to create a sterile, closed system using clinically approved tubing and sealing systems. Even when challenged with a large number of vector producer cells (2.38 x 109 cells), no viable cells are passed through the system. The step filtration system developed minimizes the titer reduction associated with filtration, provides rapid flow rates, and was cost effective when filtering volumes in excess of 2 liters.

AB - Production of retroviral vectors for clinical use requires removal of cells and cellular debris. We combined a series of filters of decreasing pore size using commercially available blood banking filters approved for clinical use. The collection bag and filters can be connected to create a sterile, closed system using clinically approved tubing and sealing systems. Even when challenged with a large number of vector producer cells (2.38 x 109 cells), no viable cells are passed through the system. The step filtration system developed minimizes the titer reduction associated with filtration, provides rapid flow rates, and was cost effective when filtering volumes in excess of 2 liters.

KW - Filtration

KW - Retroviral vector

KW - Vector titer

UR - http://www.scopus.com/inward/record.url?scp=0034515324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034515324&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3301328

DO - 10.1038/sj.gt.3301328

M3 - Article

C2 - 11175310

AN - SCOPUS:0034515324

VL - 7

SP - 1993

EP - 1998

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 23

ER -